Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

FDA Grants Fast Track Status to Paxalisib for Glioblastoma

August 20th 2020

The FDA has granted a fast track designation to paxalisib for the treatment of patients with glioblastoma.

Dr. Reardon on the Potential Utility of INO-5401 and INO-9012 in Glioblastoma

August 18th 2020

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

FDA Approval Sought for Omburtamab in Pediatric Metastatic Neuroblastoma

August 6th 2020

The biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for use in pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been submitted to the FDA under the agency’s Rolling Review process.

FDA Grants Fast Track Status to Enzastaurin for Newly Diagnosed Glioblastoma

July 22nd 2020

The FDA has granted a fast track designation for the PKCβ inhibitor enzastaurin for the treatment of patients with newly diagnosed glioblastoma.

Investigators Take Aim at GBM With a Biomarker-Driven Approach

July 21st 2020

Efforts are underway to expedite the identification of therapies that offer promise for patients with glioblastoma

Rolling BLA Submitted to FDA for Omburtamab in Pediatric Metastatic Neuroblastoma

June 30th 2020

A biologics license application has been submitted to the FDA for omburtamab, previously referred to as burtomab, for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

FDA Grants Berubicin Orphan Drug Status for Brain Cancer

June 11th 2020

The FDA has granted an orphan drug designation to berubicin for the treatment of patients with malignant gliomas.

FDA Grants Naxitamab Priority Review for Relapsed/Refractory High-Risk Neuroblastoma

June 3rd 2020

The FDA has granted a priority review designation to a biologics license application for the investigational, humanized monoclonal antibody naxitamab (Danyelza) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial

May 14th 2020

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

AV-GBM-1 Active in Frontline Glioblastoma

April 8th 2020

AV-GBM-1 showed early promise in an interim overall survival analysis of an ongoing phase II trial in patients with newly diagnosed glioblastoma.

Paxalisib Shows Positive Survival Data in Glioblastoma

April 8th 2020

Treatment with paxalisib, an investigational small molecule inhibitor of the PI3K/AKT/mTOR pathway, was associated with a positive overall survival signal in patients with glioblastoma.

FDA Approval Sought for Naxitamab in Neuroblastoma

April 4th 2020

A Biologics License Application has been filed with the FDA for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

The Importance of Combination Immune Therapy in Orthotopic Murine Glioblastoma

January 30th 2020

Connor Liu, medical student, Washington University School of Medicine, discusses the importance of combination immunotherapy in orthotopic murine glioblastoma.

Vorasidenib, Ivosidenib Show Encouraging Activity in IDH1-Mutant Low-Grade Glioma

November 26th 2019

Single-agent vorasidenib or ivosidenib led to brain penetrance and 2-hydroxyglutarate suppression in patients with low-grade glioma who harbor IDH1 mutations.

INO-5401/INO-9012 Plus Cemiplimab Hits High 6-Month PFS Rate in Newly Diagnosed GBM

November 6th 2019

The combination of INO-5401 and INO-9012 with cemiplimab, plus chemoradiation, demonstrated promising 6-month progression-free survival rates in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase methylated or unmethylated.

TOCA 511 and Toca FC Treatment Misses OS Endpoint in Glioma Trial

September 13th 2019

Treatment with Toca 511 and Toca FC did not improve overall survival compared with standard therapy in patients with recurrent high-grade glioma undergoing resection, missing the primary endpoint of the phase III Toca 5 trial.

Nivolumab Combo Misses PFS Endpoint in Newly Diagnosed MGMT-Methylated GBM

September 5th 2019

The combination of nivolumab plus standard temozolomide and radiation therapy did not show a statistically significant improvement in progression-free survival compared with temozolomide/radiation therapy alone in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase-methylated, missing one of the primary endpoints of the phase III CheckMate-548 trial.

University of Wisconsin Team Develops Novel Strategy for High-Risk Neuroblastoma

June 20th 2019

Investigators at the University of Wisconsin American Family Children’s Hospital are developing a new approach to treating patients with neuroblastoma that has the potential to improve outcomes for patients whose disease has not responded to conventional therapy.

Dr. Kumthekar Discusses Frontline Therapy for Anaplastic Astrocytoma

June 18th 2019

Priya U. Kumthekar, MD, assistant professor of neurology and medicine, Northwestern University Feinberg School of Medicine, discusses frontline therapy for patients with anaplastic astrocytoma.

Dr. Wong Discusses Recent Negative Trials in Glioblastoma

June 14th 2019

Eric T. Wong, MD, associate professor of neurology at Harvard Medical School and co-director of the Brain Tumor Center at Beth Israel Deaconess Medical Center, discusses recent negative trials in glioblastoma.